Abstract
Intestinal absorption of 131I-labeled elastase was studied in rats paying attention to the lymphatics and the portal vein as the route of absorption. 1. 1. Following the intraintestinal administration of 131I-labeled elastase in rats with thoracic duct fistula, protein-bound and immunoprecipitable radioactivity were determined in both serum and lymp. 2. 2. The amount of the absorbed immunoprecipitable radioactivity via lymphatics was 0.05 and 0.02% per 1 and 5 mg dose 131I-labeled elastase, respectively. 3. 3. The absorption of immunoprecipitable radioactivity via portal vein was calculated according to the method of J.C.K. Loo and S. Riegelman ( J. Pharm. Sci., 57 (1968) 918) using the concentration of immunoprecipitable radioactivity in serum. The amount of absorbed immunoprecipitable radioactivity via both lymphatic and portal vein routes was 0.194 and 0.053% per 1 and 5 mg dose of 131I-labeled elastase, respectively. absorption via lymphatics was 36% of the total immunoprecipitable radioactivity absorbed via both routes. The pharmacokinetic profile of 131I-labeled elastase was determined in rats following intravenous injection of 131I-labeled elastase. Serum levels declined exponentially after 1 h and the two-compartmental model was applied to analyze the time course of serum levels.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
